series-c-plus
Stage
2
Investors
About
Alumis Therapeutics develops next-generation targeted therapies for immune-mediated diseases, leveraging a proprietary data analytics platform to support precision therapeutic development and advancing a late-stage portfolio including envudeucitinib.
Explore Alumis Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.